Clinical trial

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

NCT04263051

Study summary

ClinicalTrials.gov

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention UCPVax + Nivolumab Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention standard chemotherapy Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-09-09

PhasePHASE2

Conditions

Advanced Non-small Cell Lung Cancerunresolved

Interventions

UCPVax + NivolumabDRUG

standard chemotherapyDRUG

Sponsors & collaborators

Centre Hospitalier Universitaire de Besanconlead sponsor

Bristol-Myers Squibbcollaborator

Fondation ARCcollaborator

Mapped research locations

MontpellierFrance1 BordeauxFrance1 DijonFrance1 BesançonFrance1 Saint-HerblainFrance1 ReimsFrance1 NîmesFrance1 MulhouseFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04263051 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.